AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BOTANIX PHARMACEUTICALS LTD

0.385

-0.010-2.53%

Volume:14.49M

Turnover:5.45M

Market Cap:702.87M

PE:-16.57

High:0.390

Open:0.385

Low:0.360

Close:0.395

Loading ...

Overview Company News Filings

Botanix Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Revenue

MT Newswires Live

BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$30.9 Mln

Analysts Are Optimistic We'll See A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)

Simply Wall St.

Sales Traction from Botanix Pharmaceuticals' Prescription Gel Launch May Drive Stock Re-rating, Euroz Hartleys Says

MT Newswires Live

Botanix Pharmaceuticals' Prescription Gel Commercial Launch Could Drive Stock Re-rating, Euroz Hartleys Says

MT Newswires Live

5 ASX All Ords shares starting the new year at 52-week highs

ASX Market Close: Bourse rises as Bitcoin breaks a new record | December 17, 2024

The Market Herald

Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%

MT Newswires Live

First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch

The Market Herald

The sectors and stocks set for a big 2025

There's more to Australian biotech than just CSL: the opportunities to watch

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Simply Wall St.

5 ways to identify high-quality ASX companies (and 14 stock examples)

Investing in a World of Options and Asymmetry

Botanix Labs' Mission to Bring Bitcoin to Defi Moves to Final Testnet Phase

Those who invested in Botanix Pharmaceuticals (ASX:BOT) three years ago are up 443%

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BOT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.385,"timestamp":1741151520000,"preClose":0.395,"halted":0,"volume":14489209,"delay":0,"changeRate":-0.025316,"change":-0.01,"floatShares":1585216654,"shares":1825627097,"eps":-0.023239,"lyrEps":-0.009236,"pbRate":7.6,"amount":5447091,"amplitude":0.075949,"volumeRatio":1.5718409360205559,"dividePrice":0,"prevYearClose":0.435,"fiveDayClose":0.475,"twentyDayClose":0.44},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1585216654,"roa":"-34.36%","roe":"-56.99%","lyrEps":-0.009236,"volumeRatio":1.5718409360205559,"shares":1825627097,"dividePrice":0,"high":0.39,"amplitude":0.075949,"preClose":0.395,"low":0.36,"week52Low":0.17,"pbRate":"7.60","psRate":"339.69","week52High":0.535,"institutionHeld":0,"latestPrice":0.385,"eps":-0.023239,"divideRate":0,"volume":14489209,"delay":0,"ttmEps":-0.023239,"open":0.385,"prevYearClose":0.435,"prevWeekClose":0.44,"prevMonthClose":0.44,"prevQuarterClose":0.435,"fiveDayClose":0.475,"twentyDayClose":0.44,"sixtyDayClose":0.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514089483","title":"Botanix Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514089483","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514089483?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:21","pubTimestamp":1740612075,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  reported Wednesday a fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.Revenue for the six months ended Dec. 31, 2024, was AU$345.7 million, compared with AU$377.9 million a year earlier.The company's shares fell 1% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2514022197","title":"BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$30.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022197?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:33","pubTimestamp":1740533632,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$30.9 MlnFeb 26 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:HY LOSS ATTRIBUTABLE A$30.9 MILLIONFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG12X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7502","BK7508","BK7096"],"gpt_icon":0},{"id":"2510828552","title":"Analysts Are Optimistic We'll See A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510828552","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510828552?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:47","pubTimestamp":1739227673,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Botanix Pharmaceuticals...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/analysts-are-optimistic-well-see-a-profit-from-botanix-pharm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK7502","BK7508","BOT.AU"],"gpt_icon":0},{"id":"2510886743","title":"Sales Traction from Botanix Pharmaceuticals' Prescription Gel Launch May Drive Stock Re-rating, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886743","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510886743?lang=en_us&edition=fundamental","pubTime":"2025-02-10 14:52","pubTimestamp":1739170370,"startTime":"0","endTime":"0","summary":"Sales traction from Botanix Pharmaceuticals'  full commercial launch of Sofdra, its prescription treatment for excessive underarm sweating, could lead to a potential stock rating above its price target, according to a Monday note by Euroz Harlteys.On Jan. 31, the company said that the full commercial launch of Sofdra is officially underway, with sales professionals set to hit the field within the next week.Early patient feedback from social media and online sources shows that Sofdra is effective compared to its alternatives, with minimal side effects, with patients receiving full insurance coverage, Euroz said.The feedback is positive for BOT and raises Euroz's confidence in the company's ongoing commercial rollout.Euroz maintained Botanix Pharmaceuticals' buy rating and its AU$0.55 price target.Shares of the company rose 7% at market close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2509424162","title":"Botanix Pharmaceuticals' Prescription Gel Commercial Launch Could Drive Stock Re-rating, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2509424162","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509424162?lang=en_us&edition=fundamental","pubTime":"2025-02-05 14:41","pubTimestamp":1738737683,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  is poised for a significant stock re-rating as it nears the full commercial launch of Sofdra, a prescription treatment for excessive underarm sweating, according to a Tuesday note by Euroz Harlteys.Euroz Hartleys expects sales from the launch to push the stock above Botanix Pharmaceuticals' price target.On Jan. 31, the company said that the full commercial launch of Sofdra is officially underway, with sales professionals set to hit the field within the next week.Botanix Pharmaceuticals also said a digital launch of Sofdra is scheduled for the quarter.Euroz noted that the company has completed agreements with all major health insurers in the US to ensure that Sofdra, will be covered under the insurers' plans.The agreements will make Sofdra accessible to 167 million people who are covered by these insurers, Euroz added.The company has also met the criteria for US government health programs, granting Sofdra access to an additional 80 million people starting in Mar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2500680904","title":"5 ASX All Ords shares starting the new year at 52-week highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2500680904","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500680904?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:00","pubTimestamp":1735851600,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords Index  shares closed higher on the first day of trading for 2025.The ASX All Ords finished 0.53% higher at 8,465 points on Thursday.Here are five ASX All Ords shares that started the new year on a positive note with 52-week high prices.5 ASX All Ords shares that hit 52-week highs on Thursday. It's rather fitting that the No. 1 stock among the 5 best-performing ASX All Ords stocks of 2024 started the new year at a four-year high.The Mesoblast share price reached $3.37 in intraday trading on Thursday.However, the ASX All Ords stock has been on an upward trajectory since the biotech gained approval from the United States Food and Drug Administration for its lead drug, remestemcel-L, last month.Branded Ryoncil, the drug is the first approved treatment for steroid-refractory acute graft versus host disease  in children and the first mesenchymal stromal cell  therapy approved in the US.Another ASXAll Ords techshare, Bravura Solutions, also clocked a 52-week high yesterday.AS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/5-asx-all-ords-shares-starting-the-new-year-on-52-week-highs/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PRN.AU","MSC","BOT.AU","BK7016","MSB.AU","BK7061","BK7502","BK7508","BK4150","BK4575","BK7095","BK7096","BK7503","BK7067","BVS.AU","XAO.AU","BK7501","APX.AU"],"gpt_icon":0},{"id":"2492998646","title":"ASX Market Close: Bourse rises as Bitcoin breaks a new record | December 17, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2492998646","media":"The Market Herald","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492998646?lang=en_us&edition=fundamental","pubTime":"2024-12-17 14:27","pubTimestamp":1734416820,"startTime":"0","endTime":"0","summary":"With just five trading days ‘til Christmas, the ASX closed up 0.78% at 8,314 points.Bitcoin jumped to an all-time record high above $US107,000 after Donald Trump confirmed plans for a U.S. strategic reserve for the cryptocurrency.The Iron Ore price has risen around half a percent, to US$105.50, dragging the big miners higher, whilst the big banks were the most outstanding players on the market today.Industrials, Real Estate and IT were the best performing sectors, all up around 1.3%, followed by Financials and Health Care, both up 1.1%.Novonix  closed up 3.42% on news the U.S. Department of Energy  hasconditionally committeda direct loan of up to A$1.2 billion to partially finance a proposed new facility in Tennessee.Tamboran Resources  closed up 3.85% after inking a deal with APA Group to deliver the Sturt Plateau Pipeline.Westgold Resources  closed up 4.31% on news of a potential expansion of the Fortnum Gold Operation in the Murchison Region of WA. A scoping study has identified a p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-bourse-rises-as-bitcoin-breaks-a-new-record-december-17-2024-2024-12-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CGCP","BK7084","BK7508","BK4601","LM8.AU","WGX.AU","BOT.AU","BK4585","NVX","BK7096","03439","BK7142","BK1611","83042","APA.AU","BK7506","TBN.AU","03042","IDA.AU","BK7148","09008","BK4594","BK4588","09439","BK7104","03008","BK7502","09042","BK7095","BK4157","NVX.AU"],"gpt_icon":1},{"id":"2492067557","title":"Botanix Says First Prescriptions Issued for Excessive Sweating Treatment Ahead of Q1 Commercial Launch; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492067557","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492067557?lang=en_us&edition=fundamental","pubTime":"2024-12-17 08:39","pubTimestamp":1734395992,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said the first prescriptions for its Sofdra sofpironium topical gel have been issued via telemedicine and insurance approvals, according to a Tuesday filing with the Australian bourse.Sofdra is approved by the US Food and Drug Administration for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.The drug is set for full commercial launch in the first quarter of next year, with inventory, infrastructure, and marketing and sales currently advancing, the filing said.The company's shares were down almost 3% in recent Tuesday trade.Price : $0.37, Change: $-0.01, Percent Change: -2.63%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BOT.AU","LU0426412945.USD","AUD","BK7508","BK4125","LU0426417589.USD","LU0994945656.USD","LU1043141123.HKD","BK7096","LU0345774631.USD","LU2238339852.HKD"],"gpt_icon":0},{"id":"2492671289","title":"First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2492671289","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492671289?lang=en_us&edition=fundamental","pubTime":"2024-12-17 07:25","pubTimestamp":1734391500,"startTime":"0","endTime":"0","summary":"Botanix  has reported the first prescriptions of its drug Sofdra  to treat hyperhidrosis, a condition of excessive sweating.According to Botanix, the first prescriptions were quickly followed up by the first deliveries of products to patients; the move was also a confirmation of logistics between Botanix, telehealth partners, and its patients.It’s given Botanix the chance to improve marketing and sales materials, per company statements, with a ‘sales force’ engaged and preparing for a launch meeting in late January.The company ultimately pointed to its transition to a revenue-generating company ahead of the “full commercial launch” in Q1 2025.In the company’s eyes, FDA approval was the gamechanger for the stock. And that’s reflected in the company’s share price. On a 1Y basis, BOT shares are up +153%.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certif","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/first-sofdra-prescriptions-for-excessive-sweating-condition-pushes-botanix-towards-full-commercial-launch-2024-12-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BOT.AU","BK7502","BK7096"],"gpt_icon":0},{"id":"2491504636","title":"The sectors and stocks set for a big 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2491504636","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491504636?lang=en_us&edition=fundamental","pubTime":"2024-12-16 07:40","pubTimestamp":1734306015,"startTime":"0","endTime":"0","summary":"Recovery to opportunity: Microcaps to benefit from shifting economic winds. 2024 saw a shift in performance for microcap companies after two consecutive years of challenging conditions. The S&P/ASX Emerging Companies Index has returned an impressive 27.88% . However, on a 3-year CAGR basis the index is still recovering, with a -2.40% p.a. return compared to +9.25% p.a. from the ASX 50.Healthcare: Dermatology business Botanix Pharmaceuticals  secured FDA approval for their novel drug to treat hyperhidrosis this year. The commercial launch earmarked for early 2025 will see first sales and prove out the product’s attractive economics. Dimerix  is conducting phase 3 trials for a rare kidney disease, with results expected towards the end of the calendar year. With portfolio holdings radiology business Capitol Health  and dentist franchise Pacific Smi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-sectors-and-stocks-set-for-a-big-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-sectors-and-stocks-set-for-a-big-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["MLX.AU","XJO.AU","AMI.AU","SXE.AU","BK7096","DXB.AU","XRF.AU","SND.AU","EGH.AU","GDG.AU","BK7502","XAO.AU","BK7508","BK7067","CAJ.AU","BK7507","RUL.AU","XKO.AU","BK7164","AQZ.AU","BK7133","PSQ.AU","BK7030","BK7016","BK7088","BK7124","BK7095","BK7055","BK7113","BOT.AU","BK7089","BK7501","BK7506"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["CSL","BK7501","NEU.AU","CVB.AU","SNT.AU","BK7511","BK4086","LU0728928796.USD","BK7096","OPT.AU","CSL.AU","LU1169589451.USD","BK7508","XAO.AU","BK7502","XJO.AU","DXB.AU","TLX.AU","BOT.AU","LU1169590202.USD","IMM.AU","BK7007","BK7067","SGXZ23171101.USD","SG9999004303.SGD","XKO.AU"],"gpt_icon":0},{"id":"2490840889","title":"Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490840889","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490840889?lang=en_us&edition=fundamental","pubTime":"2024-12-11 06:45","pubTimestamp":1733870757,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Botanix...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/heres-why-were-not-at-all-concerned-with-botanix-pharmaceuti-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BOT.AU","BK7096","BK7502"],"gpt_icon":0},{"id":"2489440967","title":"5 ways to identify high-quality ASX companies (and 14 stock examples)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489440967","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489440967?lang=en_us&edition=fundamental","pubTime":"2024-12-06 10:49","pubTimestamp":1733453377,"startTime":"0","endTime":"0","summary":"Whenever I ask different fund managers what quality means to them and where quality manifests in the Australian stock market, I get a different response. Yes, there are classic names like CSL and Macquarie Group, but just because a company is large does not make it a high-quality company. Nor is it the case that all small and micro-cap companies are exclusively low-quality... far from it.So, in this wire, I'm testing the concept of \"quality\" and the different qualitative measures that make up a quality stock with the help of Elise Kennedy from Schroders, Andy Forster from Argo Investments, and Kerry Series from NorthStar Impact. Together, they'll each name one stock from each of the following five categories:. \"Why I choose this company is the meaningful free cashflow and the delivery around the OPEX, w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/5-ways-to-identify-high-quality-asx-companies-and-14-stock-examples","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/5-ways-to-identify-high-quality-asx-companies-and-14-stock-examples","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7505","BK7087","BK7502","REA.AU","SDI.AU","REH.AU","TLS.AU","SDV.AU","BK7041","BK7135","BK7031","BK7042","BK7017","BK7002","APZ.AU","BK7508","BK7016","BK7064","BK7503","TWE.AU","CAR.AU","AIM.AU","WES.AU","BK7096","TNE.AU","BK7126","XRO.AU","BK7097","BOT.AU","BK7153","CBA.AU","BK7511"],"gpt_icon":0},{"id":"2489432650","title":"Investing in a World of Options and Asymmetry","url":"https://stock-news.laohu8.com/highlight/detail?id=2489432650","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489432650?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:01","pubTimestamp":1733400077,"startTime":"0","endTime":"0","summary":"“The secret to wealth is finding the asymmetric payoff—small risk, big reward” Nassim Taleb. When this writer first set about a career in finance we were tasked with uncovering how much each ASX energy company was worth, with little more direction than a basic understanding of discounted cash flows and net present values. The task was easy enough; to develop an asset by asset model that delivered a valuation per share, but how do you consider:. Specifically when it comes to oil and gas we were utilising it in the pricing of exploration plays. How does this work?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/investing-in-a-world-of-options-and-asymmetry","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/investing-in-a-world-of-options-and-asymmetry","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["MIN","LU0689626769.HKD","AFL.AU","NEU","NEU.AU","BK7504","WTC.AU","BOT.AU","BK4162","BK4211","MIN.AU","OPC.AU","BK7507","IE00BDGV0183.EUR","BK7503","BK7502","ORA","BK7067","AS","CU6.AU","TLX","LU0472753341.HKD","AFL","BK7050","BK7096","LU2506952410.USD","IE00B3PB1722.GBP","BK4133","IMR.AU","TLX.AU","LU0124676726.USD","LU2506952337.HKD","BK7508","BK7053","ASB.AU","LU0289739343.SGD","LU0511384066.AUD","TAM.AU","IE00B2PGVK34.USD","IE00BVYPNV92.GBP","ORA.AU","PET.AU","MTR.AU","PET","LU0289961442.SGD","IE00B3CCJ633.GBP","BK7115","LU2477742899.HKD","MTR","ASB"],"gpt_icon":0},{"id":"2489145700","title":"Botanix Labs' Mission to Bring Bitcoin to Defi Moves to Final Testnet Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2489145700","media":"CoinDesk","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489145700?lang=en_us&edition=fundamental","pubTime":"2024-12-05 00:25","pubTimestamp":1733329553,"startTime":"0","endTime":"0","summary":"Botanix Labs, the developer of Bitcoin layer-2 network Spiderchain, which aims to advance the possibilities of decentralized finance  on the world's original blockchain, has moved to its final testnet phase ahead of a 2025 mainnet debut.The testnet, known as Aragog, introduces tools that will form the basis for the mainnet's DeFi offering, such as bitcoin -backed stablecoin Palladium, decentralized exchange Bitzy and lending and borrowing market Spindle.Botanix Labs, which aims to introduce the mainnet in the first quarter, is building Spiderchain to be compatible with the Ethereum Virtual Machine , the software that powers the Ethereum network. The goal is to allow any application or smart contract to be copied and pasted onto Bitcoin, creating provision for the kind of DeFi applications that would generally call Ethereum home.In short, Botanix says its aim is to \"bring Bitcoin back online and onchain.\". \"Every member of the Bitcoin economy should work to ensure that demand for onchai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/botanix-labs-mission-bring-bitcoin-162553915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4588","BK4601","BTC.AU","QETH","BK7096","CETH","FETH","BOT.AU","BK4585","EZET","BK4594","BK7508","ETHV","BK7502","EVM","BTC"],"gpt_icon":1},{"id":"2485126489","title":"Those who invested in Botanix Pharmaceuticals (ASX:BOT) three years ago are up 443%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485126489","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485126489?lang=en_us&edition=fundamental","pubTime":"2024-11-21 10:49","pubTimestamp":1732157370,"startTime":"0","endTime":"0","summary":"While Botanix Pharmaceuticals Limited  shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 13% in the last quarter. But that doesn't displace its brilliant performance over three years. Indeed, the share price is up a whopping 443% in that time. So you might argue that the recent reduction in the share price is unremarkable in light of the longer term performance. The only way to form a view of whether the current price is justified is to consider the merits of the business itself.So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.In the last 3 years Botanix Pharmaceuticals saw its revenue shrink by 24% per year. This is in stark contrast to the strong share price growth of 76%, compound, per year. This clear lack of correlation between revenue and share price is surprising to see in a money losing company. At the risk of upsetting hol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-botanix-pharmaceuticals-asx-024930164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7502","BK7096","BK7508","BOT.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":22}]}}